Denenicokin
- Generic Name
- Denenicokin
- Drug Type
- Biotech
- CAS Number
- 716840-32-3
- Unique Ingredient Identifier
- A4LY1V9F0H
- Background
Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 64
- Registration Number
- NCT01152788
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath